Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396149 | 0.98 | MAPT (0.40) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Fluoride Ion SCHEMBL15993970 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Water SCHEMBL15994022 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Bromide SCHEMBL8614699 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19025641 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Hydrochloric Acid SCHEMBL316715 | 0.96 | MAPT (0.43) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Glycerin SCHEMBL3308566 | 0.91 | SLC22A16 (0.41) | MAPTSLC22A16CYP1A2MEN1LMNA | |
| SCHEMBL5582502 | 0.86 | MAPT (0.44) | MAPTSLC22A16CYP1A2TSHRMEN1 | |
| Iodide SCHEMBL9630545 | 0.84 | CES2 (0.50) | MAPTCES2CYP1A2MAPK1TSHR | |
| Iodide SCHEMBL9630733 | 0.84 | CES2 (0.50) | MAPTCES2CYP1A2MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023003524-A1 | SCREENING KIT FOR RISK OF INSECTICIDE EXPOSURE | DEMETEX SOLUTION COMPANY LIMITED (TH) | 2023-01-26 | — | — | WO | claimed |
| EP-2961268-B1 | SAMPLE FIXATION AND STABILISATION | GOLDSBOROUGH ANDREW SIMON (FR) | 2018-11-21 | — | — | EP | claimed |
| EP-2961268-A1 | SAMPLE FIXATION AND STABILISATION | Goldsborough, Andrew Simon (FR) | 2016-01-06 | — | — | EP | claimed |
| WO-2014131906-A1 | SAMPLE FIXATION AND STABILISATION | GOLDSBOROUGH ANDREW SIMON (FR) | 2014-09-04 | — | — | WO | claimed |
| US-6773822-B2 | ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. | TEMPLE-INLAND FOREST PRODUCTS CORPORATION | 2004-08-10 | — | — | US | claimed |
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20260009068-A1 | METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS | Encodia, Inc. (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2025262036-A1 | METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION | RNASSIST LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-12428673-B2 | Methods for barcoding macromolecules in individual cells | Encodia, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-119823127-A | Beta-carboline alkaloid PFT217 in gastrodia elata, and preparation method and application thereof | 中国科学院昆明植物研究所 | 2025-04-15 | — | — | CN | disclosed |
| US-20250033015-A1 | POLYDISULFIDE CORE-SHELL MICROCAPSULES | FIRMENICH SA (CH) | 2025-01-30 | — | — | US | disclosed |
| US-RE38460-E1 | Huperzine A derivatives, their preparation and their use | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2004-03-09 | — | — | US | disclosed |
| US-6680127-B2 | COMPRISING AN ANTIFUNGAL AGENT AND A RETENTION AID, SUCH AS A SURFACTANT, IN ONE OR MORE PAPER FACINGS. | TEMPLE-INLAND FOREST PRODUCTS, CORPORATION | 2004-01-20 | — | — | US | disclosed |
| EP-0806416-B1 | HUPERZINE A DERIVATIVES, THEIR PREPARATION AND THEIR USE | SHANGAHI INST MATERIA MEDICA (CN) | 2003-05-07 | — | — | EP | disclosed |
| US-20030035981-A1 | Antifungal gypsum board | TIN INC. D/B/A TEMPLE-INLAND | 2003-02-20 | — | — | US | disclosed |
| US-20030031898-A1 | Antifungal gypsum board | TIN INC. D/B/A TEMPLE-INLAND | 2003-02-13 | — | — | US | disclosed |
| US-5929084-A | Huperzine A derivatives, their preparation and their use | SHANGAHI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 1999-07-27 | — | — | US | disclosed |
| EP-0806416-A1 | HUPERZINE A DERIVATIVES, THEIR PREPARATION AND THEIR USE | TSUMURA & CO. (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-3736043-A | ELECTROCHEMICAL MOLECULAR DISPLAY AND WRITING | IBM | 1973-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SLC10A2, SLC5A7, SLC18A3 | CHRM1 10/4885MAPT 527/4885SLC22A16 129/4885 |
| US-20260009068-A1 | METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS | HNRNPAB, ACTB, SSBP1 | CHRM1 4092/4885MAPT 3693/4885SLC22A16 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.